X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Panacea Biotech Fact Sheet, Panacea Biotech Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Fact Sheet   (PANB)

Here is the latest financial fact sheet of Panacea Biotech. For more details, see the Panacea Biotech quarterly results and Panacea Biotech share price and chart. For a sector overview, read our pharmaceuticals sector report.

PANACEA BIOTECH Price History

Price Rs 263.3
Mkt Cap Rs m 16,124
Vol '000 34.1
P/E X 141.6
P/CF X -38.8
EPS (TTM) Rs 1.9
% ch % 2.8
No. of shares m 61.25
% ch week % 3.3
% ch 1-mth % 10.2
% ch 12-mth % 141.6
52 week H/L Rs 275.9/108.1
(As on Nov 22, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

PANACEA BIOTECH Financials

No. of Mths
Year Ending
12
Mar-10
*
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
5-Yr Chart
Click to enlarge
PANACEA BIOTECH EQUITY SHARE DATA
High Rs248241195159149 
Low Rs59152686482 
Sales per share (Unadj.) Rs134.7189.8115.999.384.1 
Earnings per share (Unadj.) Rs12.223.6-33.6-38.2-18.3 
Diluted earnings per shareRs13.323.6-33.6-38.2-18.3 
Cash flow per share (Unadj.) Rs19.735.8-21.0-24.2-6.7 
Dividends per share (Unadj.) Rs0.250.75000 
Adj. dividends per shareRs0.270.750.000.000.00 
Dividend yield (eoy) %0.20.4000 
Book value per share (Unadj.) Rs104.8105.9142.9102.283.7 
Adj. book value per shareRs114.4105.9142.9102.283.7 
Shares outstanding (eoy) m66.8461.2561.2561.2561.25 
Bonus/Rights/Conversions  ESOPBB--- 
Price / Sales ratio x1.11.01.11.11.4 
Avg P/E ratio x12.68.3-3.9-2.9-6.3 
P/CF ratio (eoy) x7.85.5-6.3-4.6-17.2 
Price / Book Value ratio x1.51.90.91.11.4 
Dividend payout %2.03.2000 
Avg Mkt Cap Rs m10,26012,0368,0546,7997,074 
No. of employees `0003.23.63.33.32.8 
Total wages/salary Rs m1,2721,6081,6071,4691,449 
Avg. sales/employee Rs Th2,787.93,229.82,151.81,843.91,874.1 
Avg. wages/employee Rs Th393.9446.7487.0445.3527.0 
Avg. net profit/employee Rs Th253.0401.9-623.2-709.9-407.7 
PANACEA BIOTECH INCOME DATA
Net Sales Rs m9,00211,6277,1016,0855,154 
Other income Rs m9361618854100 
Total revenues Rs m9,93811,7887,1896,1395,254 
Gross profit Rs m1,1702,549-863-861-766 
Depreciation Rs m500745771860711 
Interest Rs m3854731,0071,0381,503 
Profit before tax Rs m1,2211,492-2,553-2,704-2,881 
Minority Interest Rs m000011 
Prior Period Items Rs m-2-6-450-6 
Extraordinary Inc (Exp) Rs m017301731,771 
Tax Rs m402212-542-18817 
Profit after tax Rs m8171,447-2,057-2,343-1,121 
Gross profit margin %13.021.9-12.2-14.1-14.9 
Effective tax rate %32.914.221.26.9-0.6 
Net profit margin %9.112.4-29.0-38.5-21.8 
PANACEA BIOTECH BALANCE SHEET DATA
Current assets Rs m7,4958,1375,0154,3383,810 
Current liabilities Rs m2,0215,7615,1655,1008,365 
Net working cap to sales %60.820.4-2.1-12.5-88.4 
Current ratio x3.71.41.00.90.5 
Inventory Days Days186129198161156 
Debtors Days Days4487354267 
Net fixed assets Rs m8,6348,03612,85912,89814,480 
Share capital Rs m6761616161 
"Free" reserves Rs m6,9276,4244,3732,024903 
Net worth Rs m7,0056,4888,7516,2575,127 
Long term debt Rs m3,0854,2375,1256,8995,832 
Total assets Rs m16,85617,33919,49818,39519,433 
Interest coverage x4.24.2-1.5-1.6-0.9 
Debt to equity ratio x0.40.70.61.11.1 
Sales to assets ratio x0.50.70.40.30.3 
Return on assets %7.111.1-5.4-7.12.0 
Return on equity %11.722.3-23.5-37.4-21.9 
Return on capital %15.919.9-11.5-11.33.6 
Exports to sales %71.861.148.414.924.5 
Imports to sales %39.425.234.06.310.2 
Exports (fob) Rs m6,4657,1043,4379051,264 
Imports (cif) Rs m3,5442,9312,411385525 
Fx inflow Rs m6,5117,1463,4731,2071,539 
Fx outflow Rs m3,8923,3953,045954942 
Net fx Rs m2,6193,751428253597 
PANACEA BIOTECH CASH FLOW
From Operations Rs m 622 780 2,281 -240 599 
From Investments Rs m -1,172 120 -1,239 -612 -438 
From Financial Activity Rs m 276 -852 -1,336 1,049 -303 
Net Cashflow Rs m -275 49 -295 197 -141 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 74.5%
Foreign collaborators 0.0%
Indian inst/Mut Fund 0.6%
FIIs 1.3%
ADR/GDR 0.0%
Free float 23.6%
Shareholders 10,259
Pledged promoter(s) holding 35.1%
 

Company Information

REGD OFF Ambala - Chandigarh Highway, Lalru, Punjab - 140 501
E-MAIL companysec@panaceabiotec.com WEB www.panaceabiotec.com
TELEPHONE (011) 4157 8024 FAX (011) 4167 9070
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Skyline Financial, D-153 A, Ist Flr., Okhla Indl. Area, Phase-I, New Delhi-20
AUDITOR S. R. Batliboi & Co.
CHM: Soshil Kumar Jain COMP SEC: Vinod Goel (GM-Legal) YEAR OF INC: 1985 BSE CODE: 531349 FV (Rs): 1 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   TORRENT PHARMA  SHASUN PHARMA  J.B.CHEMICALS  WOCKHARDT LTD.  DIVIS LABORATORIES  

Compare PANACEA BIOTECH With:   TORRENT PHARMA  SHASUN PHARMA  J.B.CHEMICALS  WOCKHARDT LTD.  DIVIS LABORATORIES  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Higher; Automobile & PSU Stocks Rise(Closing)

Indian share markets continued to trade well above the dotted line in the afternoon session amid firm international markets.

Views on news

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

The Day Warren Buffett Lost All His Money(Smart Contrarian)

Nov 15, 2017

Buffett is still using the lessons he learnt that fateful day.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS